Trials / Recruiting
RecruitingNCT06967480
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
MG-EVOLUTION. Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis: A Real-World Study With Biomarker Analysis
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (estimated)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ravulizumab | Participants will receive Ravulizumab. |
Timeline
- Start date
- 2025-07-31
- Primary completion
- 2027-06-30
- Completion
- 2027-06-30
- First posted
- 2025-05-13
- Last updated
- 2026-02-05
Locations
23 sites across 1 country: Italy
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06967480. Inclusion in this directory is not an endorsement.